Urban areas might have higher costs due to increased demand and operational expenses
Wessells H, Levine N, Hadley ME, Dorr R, Hruby V (2000)
Recently, glucagon-like peptide 1 (GLP-1) receptor agonists drugs typically used to manage diabetes and support weight loss have gained attention for their potential effects on inflammatory conditions
The medication reduces appetite and slows digestion , but results require tracking what you eat , staying hydrated , moving your body , and adjusting as side effects change
Targeting galectin-3 in inflammatory and fibrotic diseases
In particular, vagal afferent neurons expressing the GLP-1R are necessary for GLP-1 mediated induction of satiety (167) but not glucose lowering effects (168)